Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ECOG performance status of ≤2.~* Relapsed or refractory disease to at least one prior systemic regimen.~* Measurable disease: according to International Working Group (IWG) guidelines for all patients with PTCL and according to CTCL Response in Skin consensus criteria for all patients with CTCL.~* Objective, documented evidence of disease progression on study entry.~Exclusion Criteria:~* Known active central nervous system (CNS) lymphoma.~* Active graft-versus-host disease after allogeneic stem cell transplantation. At least 4 months must have elapsed since completion of allogeneic stem cell transplantation.~* Unable to swallow tablets or malabsorption syndrome, disease significantly affecting gastrointestinal function.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Selinexor (Type: EXPERIMENTAL): 60 mg dose (equivalent to \~35 mg/m²)

Based on this trial design, predict the completion outcome and termination type (if applicable).